Showing 20 of 173 recruiting trials for “squamous-cell-carcinoma-of-the-hypopharynx”
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
RecruitingNCT06710665 ↗
Tumor Regression Grade As Predictor of Adjuvant Therapy
👨⚕️ Bin Zheng, Key Laboratory of Cardio-Thoracic Surgery, Fujian Medical University, Fujian Province University, Fu📍 1 site📅 Started Oct 2024View details ↗
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
👨⚕️ Tao Jiang, Dr, Tangdu hospital, The air force military university📍 1 site📅 Started Oct 2024View details ↗
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
RecruitingNCT06561178 ↗
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
👨⚕️ Hong Yang, M.D.;Ph.D., Sun Yat-Sen University Cancer Center📍 1 site📅 Started Aug 2024View details ↗
A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
👨⚕️ Li Feng, Ph.D., Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 1 site📅 Started Aug 2024View details ↗
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
👨⚕️ Xiangbo Wan, The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Aug 2024View details ↗
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
👨⚕️ Wang, 2nd Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Aug 2024View details ↗
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
👨⚕️ Bo You, Doctor, Department of Otorhinolaryngology-Head and Neck Surgery, Affiliated Hospital of Nantong University📍 1 site📅 Started Aug 2024View details ↗
Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
👨⚕️ Melvin LK CHUA, MBBS, FRCR, PhD, FAMS, National Cancer Centre, Singapore📍 2 sites📅 Started Jul 2024View details ↗
RecruitingNCT06463392 ↗
Deep Learning-based sbORN Diagnostic Model
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →